Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 10:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 1,586 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo:0.9% sodium chloride Clear all
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy Study of Meningococcal Group B Vaccine rMenB+OMV NZ (Bexsero) to Prevent Gonococcal Infection

NCT04350138
View directory record Official record
Conditions
Gonococcal Infection
Interventions
Meningococcal Group B Vaccine, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
2,606 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 16, 2026, 10:22 AM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy, Safety, Tolerability and Pharmacokinetics of MIJ821 in Participants With Treatment- Resistant Depression (TRD)

NCT05454410
View directory record Official record
Conditions
Treatment-Resistant Depression
Interventions
MIJ821 Subcutaneous Injection 1 mg, MIJ821 Subcutaneous Injection 4 mg, MIJ821 Subcutaneous Injection 10 mg, Placebo Subcutaneous Injection
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
3
States / cities
Birmingham, Alabama • Oakland Park, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 13, 2025 · Synced Oct 16, 2026, 10:22 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Dexamethasone for the Prevention of Post-operative Nausea and Vomiting in Patients Undergoing Cesarean Sections

NCT01734161
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
Dexamethasone, Placebo
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 46 Years · Female only
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Oct 16, 2026, 10:22 AM EDT
Completed Phase 2 Interventional

Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy

NCT01079325
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Polyneuropathy
Interventions
SB-509, Saline
Drug · Other
Lead sponsor
Sangamo Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
31
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated May 23, 2022 · Synced Oct 16, 2026, 10:22 AM EDT
Completed Phase 4 Interventional Results available

Assessing the Use of Certolizumab Pegol in Adult Subjects With Rheumatoid Arthritis on the Antibody Response When Receiving Influenza Virus and Pneumococcal Vaccines

NCT00993668
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo, Certolizumab pegol
Other · Biological
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
41
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 16, 2026, 10:22 AM EDT
Completed Phase 2 Interventional Results available

DaxibotulinumtoxinA for Injection for the Treatment of Plantar Fasciitis

NCT03825315
View directory record Official record
Conditions
Plantar Fasciitis
Interventions
DAXI 80 U, DAXI 120 U, Placebo
Biological · Other
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
20
States / cities
Tucson, Arizona • Carmichael, California • Castro Valley, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 16, 2026, 10:22 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age

NCT05992935
View directory record Official record
Conditions
Norovirus Acute Gastroenteritis
Interventions
mRNA-1403, mRNA-1405, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,407 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
14
States / cities
Long Beach, California • Longmont, Colorado • Hollywood, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 16, 2026, 10:22 AM EDT
Completed Phase 1 Interventional Results available

A Study of LY3113593 in Participants With Chronic Kidney Disease

NCT02604160
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
LY3113593, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
Orlando, Florida • Indianapolis, Indiana • Shreveport, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2019 · Synced Oct 16, 2026, 10:22 AM EDT
Completed Phase 2 Interventional Results available

Thiamine as Adjunctive Therapy for Diabetic Ketoacidosis

NCT03717896
View directory record Official record
Conditions
Diabetic Ketoacidosis
Interventions
200mg IV thiamine in 50mL 0.9% saline, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 16, 2026, 10:22 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older

NCT04537208
View directory record Official record
Conditions
COVID-19 (Healthy Volunteers)
Interventions
CoV2 preS dTM-AF03 (low-dose), CoV2 preS dTM-AF03 (high-dose), CoV2 preS dTM-AS03 (low-dose), CoV2 preS dTM-AS03 (high-dose), CoV2 preS dTM (high-dose) without adjuvant, Placebo (0.9% normal saline)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
441 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
11
States / cities
Birmingham, Alabama • Rolling Hills Estates, California • Hollywood, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 16, 2026, 10:22 AM EDT
Terminated Phase 4 Interventional Results available

Aerosolized Antibiotics in the Treatment of Ventilator Associated Pneumonia

NCT02478710
View directory record Official record
Conditions
Pneumonia, Ventilator-Associated
Interventions
Aerosolized Tobramycin or Vancomycin, Aerosolized Placebo
Drug
Lead sponsor
Wright State University
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated May 31, 2023 · Synced Oct 16, 2026, 10:22 AM EDT
Completed Phase 2 Interventional Results available

Prospective Randomized Controlled Trial for Pain Relief After Office Ureteral Stent Removal

NCT04112160
View directory record Official record
Conditions
Pain, Urinary Stone, Urinary Calculi
Interventions
Ketorolac, normal saline
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 79 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 10, 2024 · Synced Oct 16, 2026, 10:22 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Trial of PledOx + FOLFOX6 Compared to Placebo + FOLFOX6 in Patients With Metastatic Colorectal Cancer

NCT01619423
View directory record Official record
Conditions
Advanced Metastatic (Stage IV) Colorectal Cancer
Interventions
PledOx (2 µmol/kg), PledOx (5 µmol/kg), PledOx (10 µmol/kg), Placebo (0,9% NaCl)
Drug
Lead sponsor
Egetis Therapeutics AB (publ)
Industry
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
6
States / cities
La Jolla, California • Bethesda, Maryland • Chattanooga, Tennessee + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2018 · Synced Oct 16, 2026, 10:22 AM EDT
Active, not recruiting Phase 2 Interventional

Ketamine for Methamphetamine Use Disorder

NCT06496750
View directory record Official record
Conditions
Substance Use Disorders, Substance Use, Methamphetamine Abuse
Interventions
Ketamine Hydrochloride, Midazolam Hydrochloride
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
5
States / cities
San Leandro, California • Albuquerque, New Mexico • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 16, 2026, 10:22 AM EDT
Terminated Phase 2 Interventional Results available

Proof of Concept (POC) in Patients With Ischaemic Stroke

NCT01808261
View directory record Official record
Conditions
Cerebrovascular Accident
Interventions
GSK249320 100/mg, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 90 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
6
States / cities
Orange, California • Jacksonville, Florida • Peoria, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 16, 2026, 10:22 AM EDT
Completed Phase 2 Interventional Results available

Treatment of Rett Syndrome With Recombinant Human IGF-1

NCT01777542
View directory record Official record
Conditions
Rett Syndrome
Interventions
Recombinant Human Insulin Growth Factor 1 (rhIGF-1), Placebo
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
2 Years to 10 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 26, 2018 · Synced Oct 16, 2026, 10:22 AM EDT
Completed Phase 4 Interventional Results available

The Impact of Perioperative Ketamine Infusion on Surgical Recovery

NCT04625283
View directory record Official record
Conditions
Opioid Use, Enhanced Recovery After Surgery, Anesthesia, Ketamine, Pain, Postoperative
Interventions
Ketamine, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
1,570 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 16, 2026, 10:22 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A

NCT05567783
View directory record Official record
Conditions
Influenza A
Interventions
VIR-2482 (450 mg), VIR-2482 (1200 mg), Placebo
Biological
Lead sponsor
Vir Biotechnology, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
2,977 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
51
States / cities
Anniston, Alabama • Mobile, Alabama • Tempe, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 16, 2026, 10:22 AM EDT
Not listed Phase 4 Interventional

Intraoperative Low-dose Ketamine Infusion as the Main Analgesic in Burn Patients

NCT03049930
View directory record Official record
Conditions
Burns
Interventions
Ketamine, Sodium chloride
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years to 80 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 14, 2019 · Synced Oct 16, 2026, 10:22 AM EDT
Terminated Early Phase 1 Interventional

Blood Pressure Lowering Effects of Angiotensin-(1-7) in Primary Autonomic Failure

NCT02591173
View directory record Official record
Conditions
Autonomic Nervous System Disorders, Pure Autonomic Failure, Shy-Drager Syndrome, Orthostatic Hypotension, Dysautonomic
Interventions
Angiotensin-(1-7), Saline
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 12, 2021 · Synced Oct 16, 2026, 10:22 AM EDT
Completed Phase 2 Interventional Results available

Magnesium for Peroral Endoscopic Myotomy

NCT04638881
View directory record Official record
Conditions
Esophageal Spasm
Interventions
Magnesium sulfate, Normal Saline
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 21, 2024 · Synced Oct 16, 2026, 10:22 AM EDT
Recruiting Phase 3 Interventional

Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia

NCT06597019
View directory record Official record
Conditions
Familial Hypercholesterolemia - Heterozygous
Interventions
Inclisiran, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 11 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
9
States / cities
San Francisco, California • Washington D.C., District of Columbia • Boca Raton, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 16, 2026, 10:22 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)

NCT01212094
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Rituximab, normal saline
Drug · Other
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 28, 2016 · Synced Oct 16, 2026, 10:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety and Immunogenicity Study of Intranasal Sendai Virus Vectored Respiratory Syncytial Virus (SeVRSV) Vaccine in Healthy Adults

NCT03473002
View directory record Official record
Conditions
Antiviral Prophylaxis, Respiratory Syncytial Virus Infection
Interventions
Placebo, SeVRSV Vaccine
Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 1, 2019 · Synced Oct 16, 2026, 10:22 AM EDT